To gain a deeper understanding of the underlying mechanism and explore potential therapeutic avenues, we opted to treat these FLT3-ITD leukemic cells with a HIF-1α inhibitor, given previous reports indicating that HIF-1α drives pro-survival signaling pathways in AML (18, 19). The gene discussed is FLT3; the disease is acute myeloid leukemia.